Anavex Life Sciences Appoints Terrie Kellmeyer, Ph.D., as Permanent President and CEO to Lead Clinical Development Strategy

New York, NY, November 3, 2026 (Yahoo Finance) -- Anavex Life Sciences Corp. (NASDAQ: AVXL), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (CNS) diseases, has appointed Terrie Kellmeyer, Ph.D., as President and Chief Executive Officer, effective November 1, 2026. Kellmeyer, who previously served as the company's Interim CEO, will also join its Board of Directors. She brings more than 30 years of biopharmaceutical industry experience spanning clinical development, regulatory affairs, clinical operations, and medical affairs.

Read full article here.